Why Does Calibrate Need Lab Work and What Can I Expect for My Lab Order?

The Short Answer: Labs Are a Medical Safeguard, Not a Formality

Calibrate orders labs because a GLP-1 prescription is a medical intervention, not an over-the-counter product. A physician cannot responsibly prescribe semaglutide or tirzepatide without knowing your kidney function, liver enzymes, thyroid-stimulating hormone level, and glycemic status. Those four data points alone can reveal conditions that either change the dose or rule out GLP-1 therapy entirely.

The FDA-approved prescribing information for semaglutide (Ozempic, Wegovy) carries a black-box warning about the risk of thyroid C-cell tumors observed in rodent studies, with a contraindication for patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2). [1] A TSH result outside the normal range (0.4 to 4.0 mIU/L) prompts further evaluation before any prescription is finalized.

Why Telehealth Practices Are Required to Order Labs

The American Association of Clinical Endocrinology (AACE) 2023 obesity guidelines state that weight-management pharmacotherapy should be "initiated only after a thorough medical evaluation including laboratory assessment of metabolic comorbidities." [2] Telehealth does not exempt a practice from that standard. Calibrate's physicians follow the same duty-of-care obligations as an in-person endocrinology clinic.

Omitting baseline labs would expose both the patient and the prescribing physician to preventable harm. Undiagnosed chronic kidney disease (CKD), for example, affects an estimated 37 million Americans according to CDC data. [3] GLP-1 receptor agonists require dose caution in moderate-to-severe CKD (eGFR <45 mL/min/1.73 m²), and a creatinine and eGFR value from a comprehensive metabolic panel catches that risk before the first injection.

What Tests Are Included in the Calibrate Lab Panel?

The standard Calibrate baseline panel covers six major test categories. Each one feeds a specific clinical decision.

Comprehensive Metabolic Panel (CMP)

The CMP measures 14 analytes in a single draw: sodium, potassium, bicarbonate, chloride, blood urea nitrogen (BUN), creatinine, eGFR, glucose, calcium, total protein, albumin, bilirubin, AST, and ALT. [4]

Liver enzymes (AST, ALT) matter because non-alcoholic fatty liver disease (NAFLD) is present in roughly 25% of the global population and up to 75% of people with obesity. [5] GLP-1 agents show hepatoprotective effects in clinical trials, but a markedly elevated ALT (more than three times the upper limit of normal) warrants physician review before starting any new medication. The kidney markers (BUN, creatinine, eGFR) flag CKD as described above.

Lipid Panel

A fasting lipid panel measures total cholesterol, LDL, HDL, and triglycerides. The American Heart Association recommends fasting for 9 to 12 hours before the draw for the most accurate triglyceride reading. [6] Triglycerides above 500 mg/dL signal a risk for acute pancreatitis, and GLP-1 therapy can modestly lower triglycerides (semaglutide reduced them by 18.5% vs. Placebo in the SUSTAIN-6 trial, N=3,297). [7] Knowing your starting lipid profile lets the physician track that benefit over time.

Hemoglobin A1c (HbA1c)

HbA1c reflects your average blood glucose over the preceding 8 to 12 weeks. [8] The American Diabetes Association defines prediabetes as HbA1c 5.7 to 6.4% and type 2 diabetes as HbA1c 6.5% or higher. [9] A result of 6.5% or above changes the clinical picture significantly: the physician may need to coordinate with your primary care provider, adjust the GLP-1 agent selected, and set more frequent follow-up intervals.

The ADA's Standards of Medical Care in Diabetes 2024 state: "For most nonpregnant adults with type 2 diabetes, an HbA1c goal of <7% (53 mmol/mol) is appropriate." [9] That benchmark becomes your personal target once treatment begins.

Thyroid-Stimulating Hormone (TSH)

TSH screens for both hypothyroidism and hyperthyroidism, conditions that independently affect weight, cardiovascular risk, and medication metabolism. Untreated hypothyroidism can mimic or worsen insulin resistance, confounding weight-loss outcomes. The normal reference range at most labs is 0.4 to 4.0 mIU/L, though some endocrinology societies use 0.5 to 3.0 mIU/L for treatment thresholds. [10]

Because of the MTC black-box warning, any TSH result that prompts further thyroid workup will delay the GLP-1 prescription until the physician clears you.

Fasting Plasma Glucose

A standalone fasting glucose is often included alongside the CMP glucose to confirm the overnight fasting state and provide a second glycemic data point. Normal is <100 mg/dL; impaired fasting glucose is 100 to 125 mg/dL; 126 mg/dL or above on two separate occasions meets the ADA's diagnostic criterion for type 2 diabetes. [9]

Complete Blood Count (CBC)

The CBC measures red blood cells, white blood cells, platelets, hemoglobin, and hematocrit. Anemia (hemoglobin <12 g/dL in women, <13 g/dL in men) can cause fatigue that overlaps with GLP-1 side effects such as nausea, making the two harder to distinguish without a baseline. A CBC also provides a snapshot of immune status and clotting ability before any medication change. [11]

Why GLP-1 Medications Specifically Require Baseline Labs

GLP-1 receptor agonists are not vitamins. Semaglutide 2.4 mg (Wegovy) produced 14.9% mean body-weight reduction at 68 weeks in STEP-1 (N=1,961) versus 2.4% with placebo. [12] That magnitude of metabolic change affects multiple organ systems simultaneously, which is exactly why pre-treatment data matter.

Pancreatitis Risk Surveillance

The FDA labeling for all GLP-1 agents notes post-marketing reports of acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis. [1] A baseline amylase or lipase is not always standard in a metabolic panel, but if your intake form reveals a history of gallstones, heavy alcohol use, or prior pancreatitis, the Calibrate physician may add those enzymes to your order. Patients with a history of pancreatitis are generally not candidates for GLP-1 therapy. [1]

Kidney Function and Dehydration Risk

Nausea and vomiting are the most common GLP-1 side effects, occurring in 20 to 44% of participants in the STEP trials at some point during dose escalation. [12] Fluid losses from nausea can worsen kidney function acutely, particularly in someone who already has an eGFR in the 45 to 59 mL/min/1.73 m² range (CKD stage 3a). A baseline creatinine means any follow-up result can be compared to a known starting point rather than estimated. [4]

Thyroid Cancer Contraindication Screening

Rodent studies showed dose-dependent and duration-dependent thyroid C-cell hyperplasia and carcinoma with GLP-1 receptor agonists. The clinical relevance in humans remains under evaluation, but the FDA's position is firm: patients with personal or family history of MTC or MEN2 must not use semaglutide or liraglutide. [1] TSH alone does not diagnose MTC, but an abnormal TSH triggers a clinical conversation that may include neck palpation, calcitonin measurement, or referral to endocrinology before any prescription is written.

What to Expect During the Lab Order Process

Step 1: Digital Lab Requisition

After your intake questionnaire and video or asynchronous consultation with a Calibrate-affiliated physician, you receive a digital lab requisition by email or inside the Calibrate app. The order is typically sent to Quest Diagnostics or LabCorp, which together operate more than 2,000 patient service centers across the United States. [13]

You do not need to print anything. The QR code or order number in the app is sufficient at the front desk.

Step 2: Scheduling and Fasting

Schedule your appointment for the morning, before eating. An 8-to-12-hour fast is required for accurate glucose and triglyceride readings. Water, black coffee (without cream or sugar), and most prescription medications are generally permitted during the fast, but confirm with the lab or your physician if you take medications with food requirements.

Arriving between 7:00 a.m. And 9:00 a.m. On a weekday typically means shorter wait times at Quest and LabCorp locations.

Step 3: The Blood Draw

The actual blood draw takes 5 to 10 minutes. A phlebotomist collects 2 to 5 tubes of blood, depending on the number of tests ordered. You can resume normal eating and activity immediately afterward.

Step 4: Results Turnaround

Most results are available within 2 to 5 business days and are uploaded directly to your Calibrate provider. You will typically receive a notification through the app when results are ready. Calibrate's clinical team reviews results and contacts you if any value requires immediate attention or disqualifies GLP-1 therapy.

Step 5: Physician Review and Prescription Decision

Normal results across all panels generally allow the physician to issue a GLP-1 prescription within 1 to 3 business days of result receipt. Borderline or abnormal results trigger a follow-up message or call. The physician may request an additional test, ask you to consult your primary care provider, or adjust the treatment plan before prescribing.

The framework above, which the HealthRX medical team uses to triage Calibrate-equivalent telehealth lab results, organizes findings into three lanes: Green (all values within normal range, proceed with prescription), Yellow (one or more values mildly abnormal, physician review required before prescribing), and Red (contraindication identified, GLP-1 therapy paused pending specialist input or additional testing). This triage structure mirrors the approach described in AACE's 2023 obesity algorithm. [2]

How Lab Results Shape Your GLP-1 Dose and Timeline

HbA1c and Starting Dose

Patients with HbA1c between 5.7% and 6.4% (prediabetes) are often started on the standard Wegovy dose-escalation schedule: 0.25 mg semaglutide weekly for 4 weeks, advancing by 0.25 mg increments every 4 weeks to a maintenance dose of 2.4 mg weekly. [1]

Patients with HbA1c 6.5% or above may be steered toward Ozempic (semaglutide for type 2 diabetes, up to 2 mg weekly) or tirzepatide (Mounjaro/Zepbound), which has shown superior HbA1c reduction. The SURPASS-2 trial (N=1,879) found tirzepatide 15 mg reduced HbA1c by 2.46 percentage points vs. 1.86 percentage points with semaglutide 1 mg at 40 weeks (P<0.001). [14]

Lipids and Cardiovascular Risk Stratification

An LDL above 190 mg/dL or a 10-year ASCVD risk score above 20% (calculated from the CMP and lipid panel) may prompt simultaneous statin initiation per ACC/AHA 2019 cholesterol guidelines. [15] The Calibrate physician may coordinate this with your primary care provider rather than managing both conditions directly, depending on state prescribing rules.

TSH and Weight-Loss Expectations

Untreated hypothyroidism blunts the metabolic response to dietary and pharmacologic interventions. A TSH above 4.0 mIU/L with confirmatory free T4 below 0.8 ng/dL (hypothyroidism) will generally be addressed before GLP-1 therapy begins, because levothyroxine correction may itself improve insulin sensitivity and lipid profile, changing the medication decision. [10]

Follow-Up Labs: What Happens After You Start Treatment

Calibrate's protocol typically repeats the core metabolic panel at 3 months and again at 6 months. This schedule aligns with the ADA's recommendation for HbA1c monitoring every 3 months when therapy is adjusted and every 6 months once stable glycemic control is achieved. [9]

At the 3-month mark, the physician looks for:

• HbA1c reduction of at least 0.3 to 0.5 percentage points (indicating glycemic response)
• Triglyceride reduction (semaglutide's 18.5% reduction in SUSTAIN-6 [7] is a reasonable benchmark)
• Stable creatinine and eGFR (no acute kidney injury from nausea-related dehydration)
• ALT normalization if it was mildly elevated at baseline (consistent with GLP-1's hepatoprotective effect shown in a 2021 meta-analysis of 11 RCTs, N=936). [5]

Weight loss that is less than 5% of body weight by week 16 on a full maintenance dose is considered an inadequate response per FDA prescribing guidance and AACE recommendations, and the medication plan should be reassessed. [2]

Insurance, Cost, and Lab Access

Most commercial insurance plans cover the Calibrate lab panel under preventive-care or diagnostic-testing benefits with no out-of-pocket cost to the member, though coverage varies by employer and plan design. Patients on high-deductible health plans may owe a portion until their deductible is met.

Cash-pay pricing at Quest and LabCorp for a comparable metabolic panel ranges from roughly $80 to $250 depending on the specific tests included and geographic location. Calibrate's member services team can provide an itemized test list to submit for reimbursement or HSA/FSA coverage.

The CDC notes that more than 96 million American adults have prediabetes, and 80% of them do not know it. [3] For many Calibrate members, the baseline lab panel is the first time they have seen an HbA1c result, making the process educational as well as clinical.

Preparing for Your Lab Draw: A Practical Checklist

The following steps reduce the chance of a rejected result or a repeat draw:

• Fast for 8 to 12 hours (water and plain medications permitted).
• Bring a government-issued photo ID and your insurance card to the lab.
• Show the lab order QR code from the Calibrate app or email at check-in.
• Drink 8 to 16 ounces of water before the draw; hydration makes veins easier to access.
• Avoid strenuous exercise for 24 hours before the draw, as intense activity can transiently raise creatinine and AST. [4]
• If you take biotin (vitamin B7) supplements, stop them 72 hours before the draw; biotin at doses above 5 mg/day interferes with TSH immunoassays and can produce falsely low or high results per FDA safety communication. [16]

The biotin interference point is worth particular attention because many multivitamins marketed for hair, skin, and nails contain 5,000 to 10,000 mcg (5 to 10 mg) of biotin, which is enough to skew a TSH result and potentially delay your prescription.